<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="td" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">td</book-part-id>
      <title-group>
        <title>Thanatophoric Dysplasia</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Karczeski</surname>
            <given-names>Barbara</given-names>
          </name>
          <xref ref-type="aff" rid="td.AFF1"/>
          <degrees>MS, MA</degrees>
          <email>bkarczes@jhmi.edu</email>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Cutting</surname>
            <given-names>Garry R</given-names>
          </name>
          <xref ref-type="aff" rid="td.AFF2"/>
          <degrees>MD</degrees>
          <email>gcutting@jhmi.edu</email>
        </contrib>
      </contrib-group>
      <aff id="td.AFF1">DNA Diagnostic Laboratory<break/>Johns Hopkins University<break/>Baltimore, Maryland</aff>
      <aff id="td.AFF2">DNA Diagnostic Laboratory<break/>Johns Hopkins University<break/>Baltimore, Maryland</aff>
      <pub-history>
        <date iso-8601-date="2004-05-21" date-type="created">
          <day>21</day>
          <month>05</month>
          <year>2004</year>
        </date>
        <date iso-8601-date="2013-09-12" date-type="updated">
          <day>12</day>
          <month>09</month>
          <year>2013</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="tetra-amelia" document-type="chapter">Tetra-Amelia Syndrome</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="trma" document-type="chapter">Thiamine-Responsive Megaloblastic Anemia Syndrome</related-object>
      <abstract id="td.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>Thanatophoric dysplasia (TD) is a short-limb dwarfism syndrome that is usually lethal in the perinatal period. TD is divided into type I, characterized by micromelia with bowed femurs and, uncommonly, the presence of cloverleaf skull deformity (<italic toggle="yes">Kleeblattsch&#x000e4;del</italic>) of varying severity; and type II, characterized by micromelia with straight femurs and uniform presence of moderate-to-severe cloverleaf skull deformity. Other features common to type I and type II include: short ribs, narrow thorax, macrocephaly, distinctive facial features, brachydactyly, hypotonia, and redundant skin folds along the limbs. Most affected infants die of respiratory insufficiency shortly after birth. Rare long-term survivors have been reported.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>Diagnosis of TD is based on clinical examination and/or prenatal ultrasound examination and radiologic studies. Characteristic histopathology is also present. <italic toggle="yes">FGFR3</italic> is the only gene in which mutation is known to cause TD. Up to 99% of mutations causing TD type I and more than 99% of mutations causing TD type II can be identified through molecular genetic testing of <italic toggle="yes">FGFR3</italic>.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Management focuses on the parents' wishes for provision of comfort-care for the newborn. Newborns require respiratory support (with tracheostomy and ventilation) to survive. Anesthetic management may include: intubation with a flexible fiberoptic scope with the cervical spine in a neutral position; use of evoked potential monitoring during the procedure; and avoidance of volatile anesthetic agents and muscle relaxants that may interfere with evoked potential recordings. Other treatment measures may include: antiepileptic drugs to control seizures, shunt placement for hydrocephaly, suboccipital decompression for relief of craniocervical junction constriction, and hearing aids. </p>
          <p><italic toggle="yes">Surveillance</italic>: Long-term survivors need neurologic, orthopedic, and audiologic evaluations, CT to monitor for craniocervical constriction, and EEG to monitor for seizure activity.</p>
          <p><italic toggle="yes">Pregnancy management</italic>: When TD is diagnosed prenatally, treatment goals are to avoid potential pregnancy complications including prematurity, polyhydramnios, malpresentation, and delivery complications from macrocephaly and/or a flexed and rigid neck; cephalocentesis and cesarean section may be considered to avoid maternal complications.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>TD is inherited in an autosomal dominant manner; the majority of probands have <italic toggle="yes">de novo</italic> mutation of <italic toggle="yes">FGFR3</italic>. Risk of recurrence for parents who have had one affected child is not significantly increased over that of the general population. Germline mosaicism in healthy parents, although not previously reported, remains a theoretic possibility. Prenatal diagnosis is possible by ultrasound examination and molecular genetic testing.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="td.Diagnosis">
        <title>Diagnosis</title>
        <sec id="td.Clinical_Diagnosis">
          <title>Clinical Diagnosis</title>
          <p>Thanatophoric dysplasia (TD) is one of the short-limb dwarfism conditions suspected when significantly shortened long bones and a narrow thorax are detected prenatally or neonatally, especially when perinatal death occurs.</p>
          <p><bold>Prenatal ultrasound examination</bold> [<xref ref-type="bibr" rid="td.REF.debiasio.2000.835">De Biasio et al 2000</xref>, <xref ref-type="bibr" rid="td.REF.chen.2001.89">Chen et al 2001</xref>, <xref ref-type="bibr" rid="td.REF.ferreira.2004.241">Ferreira et al 2004</xref>, <xref ref-type="bibr" rid="td.REF.debiasio.2005.426">De Biasio et al 2005</xref>, <xref ref-type="bibr" rid="td.REF.tonni.2010.314">Tonni et al 2010</xref>, <xref ref-type="bibr" rid="td.REF.khalil.2011.115">Khalil et al 2011</xref>, <xref ref-type="bibr" rid="td.REF.martinezfrias.2011.197">Mart&#x000ed;nez-Frias et al 2011</xref>] findings by trimester include the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>
                <bold>First trimester</bold>
              </p>
              <list list-type="bullet">
                <list-item>
                  <p>Shortening of the long bones, possibly visible as early as 12 to 14 weeks' gestation</p>
                </list-item>
                <list-item>
                  <p>Increased nuchal translucency</p>
                </list-item>
                <list-item>
                  <p>Reverse flow in the ductus venosus (one case report), possibly the result of the narrow thorax compressing vascular flow</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>
                <bold>Second/third trimester</bold>
              </p>
              <list list-type="bullet">
                <list-item>
                  <p>Growth deficiency with limb length below fifth centile recognizable by 20 weeks' gestation</p>
                </list-item>
                <list-item>
                  <p>Well-ossified spine and skull</p>
                </list-item>
                <list-item>
                  <p>Platyspondyly</p>
                </list-item>
                <list-item>
                  <p>Ventriculomegaly</p>
                </list-item>
                <list-item>
                  <p>Narrow chest cavity with short ribs</p>
                </list-item>
                <list-item>
                  <p>Polyhydramnios</p>
                </list-item>
                <list-item>
                  <p>Bowed femurs (TD type I)</p>
                </list-item>
                <list-item>
                  <p>Encephalocele (infrequently; other brain abnormalities also described) </p>
                </list-item>
                <list-item>
                  <p>Cloverleaf skull (<italic toggle="yes">Kleeblattsch&#x000e4;del</italic>) (often in TD type II; occasionally in TD type I) and/or relative macrocephaly</p>
                </list-item>
              </list>
            </list-item>
          </list>
          <p>Note: Although identification of a lethal skeletal dysplasia in the second trimester is often straightforward, establishing the specific diagnosis can be difficult [<xref ref-type="bibr" rid="td.REF.parilla.2003.255">Parilla et al 2003</xref>, <xref ref-type="bibr" rid="td.REF.krakow.2008.1917">Krakow et al 2008</xref>, <xref ref-type="bibr" rid="td.REF.schramm.2009.160">Schramm et al 2009</xref>]. Ultrasound examination or review of the ultrasound films by an OB/geneticist may be most helpful in making a specific diagnosis prenatally. A three-dimensional ultrasound examination may also aid in visualizing facial features and other soft tissue findings of TD [<xref ref-type="bibr" rid="td.REF.chen.2001.89">Chen et al 2001</xref>].</p>
          <p><bold>Postnatal physical examination</bold> [<xref ref-type="bibr" rid="td.REF.lemyre.1999.185">Lemyre et al 1999</xref>, <xref ref-type="bibr" rid="td.REF.passosbueno.1999.115">Passos-Bueno et al 1999</xref>, <xref ref-type="bibr" rid="td.REF.debiasio.2000.835">De Biasio et al 2000</xref>]:</p>
          <list list-type="bullet">
            <list-item>
              <p>Macrocephaly</p>
            </list-item>
            <list-item>
              <p>Large anterior fontanel</p>
            </list-item>
            <list-item>
              <p>Frontal bossing, flat facies with a depressed nasal bridge, ocular proptosis</p>
            </list-item>
            <list-item>
              <p>Marked shortening of the limbs (micromelia)</p>
            </list-item>
            <list-item>
              <p>Trident hand with brachydactyly</p>
            </list-item>
            <list-item>
              <p>Redundant skin folds</p>
            </list-item>
            <list-item>
              <p>Narrow bell-shaped thorax with short ribs and protuberant abdomen</p>
            </list-item>
            <list-item>
              <p>Relatively normal trunk length</p>
            </list-item>
            <list-item>
              <p>Generalized hypotonia</p>
            </list-item>
            <list-item>
              <p>Bowed femurs (TD type I)</p>
            </list-item>
            <list-item>
              <p>Cloverleaf skull (always in TD type II; sometimes in TD type I)</p>
            </list-item>
          </list>
          <p><bold>Radiographs/other imaging studies</bold> [<xref ref-type="bibr" rid="td.REF.wilcox.1998.274">Wilcox et al 1998</xref>, <xref ref-type="bibr" rid="td.REF.lemyre.1999.185">Lemyre et al 1999</xref>]:</p>
          <list list-type="bullet">
            <list-item>
              <p>Rhizomelic shortening of the long bones</p>
            </list-item>
            <list-item>
              <p>Irregular metaphyses of the long bones</p>
            </list-item>
            <list-item>
              <p>Platyspondyly</p>
            </list-item>
            <list-item>
              <p>Small foramen magnum with brain stem compression</p>
            </list-item>
            <list-item>
              <p>CNS abnormalities including temporal lobe malformations, hydrocephaly, brain stem hypoplasia, neuronal migration abnormalities</p>
            </list-item>
            <list-item>
              <p>Bowed femurs (TD type I)</p>
            </list-item>
            <list-item>
              <p>Cloverleaf skull (always in TD type II; sometimes in TD type I)</p>
            </list-item>
          </list>
          <p><bold>Other reported findings</bold> include cardiac defects (patent ductus arteriosis and atrial septal defect) and renal abnormalities.</p>
        </sec>
        <sec id="td.Molecular_Genetic_Testing">
          <title>Molecular Genetic Testing</title>
          <p><bold>Gene.</bold>
<italic toggle="yes">FGFR3</italic> is the only gene in which mutation is known to cause TD type I and TD type II. The <italic toggle="yes">FGFR3</italic> mutation <xref ref-type="table" rid="td.T.selected_fgfr3_allelic_variants">p.Lys650Glu</xref> has been identified in all individuals with TD type II [<xref ref-type="bibr" rid="td.REF.bellus.2000.1411">Bellus et al 2000</xref>]. </p>
          <p>
            <bold>Clinical testing</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Sequence analysis of the entire <italic toggle="yes">FGFR3</italic> coding region</bold> is not clinically indicated for TD as there is no increase in test sensitivity, and test specificity may decrease as a result of the finding of novel variants of uncertain clinical significance. </p>
            </list-item>
          </list>
          <table-wrap id="td.T.molecular_genetic_testing_used_in_t" position="anchor" orientation="portrait">
            <label>Table 1.</label>
            <caption>
              <p>Molecular Genetic Testing Used in Thanatophoric Dysplasia</p>
            </caption>
            <table>
              <tbody>
                <tr>
                  <th id="hd_b_td.T.molecular_genetic_testing_used_in_t_1_1_1_1" align="left" valign="middle" rowspan="2" colspan="1" headers="hd_b_td.T.molecular_genetic_testing_used_in_t_1_1_1_1">Gene&#x000a0;<sup>1</sup></th>
                  <th id="hd_b_td.T.molecular_genetic_testing_used_in_t_1_1_1_2" align="left" valign="middle" rowspan="2" colspan="1" headers="hd_b_td.T.molecular_genetic_testing_used_in_t_1_1_1_2">Test Method</th>
                  <th id="hd_b_td.T.molecular_genetic_testing_used_in_t_1_1_1_3" align="left" valign="middle" rowspan="2" colspan="1" headers="hd_b_td.T.molecular_genetic_testing_used_in_t_1_1_1_3">Mutations Detected&#x000a0;<sup>2</sup></th>
                  <th id="hd_b_td.T.molecular_genetic_testing_used_in_t_1_1_1_4" colspan="2" align="left" valign="middle" rowspan="1">Mutation Detection Frequency by Test Method and Phenotype&#x000a0;<sup>3</sup></th>
                </tr>
                <tr>
                  <th headers="hd_b_td.T.molecular_genetic_testing_used_in_t_1_1_1_4" id="hd_b_td.T.molecular_genetic_testing_used_in_t_1_1_2_1" align="left" valign="middle" rowspan="1" colspan="1">TD Type I</th>
                  <th headers="hd_b_td.T.molecular_genetic_testing_used_in_t_1_1_1_4" id="hd_b_td.T.molecular_genetic_testing_used_in_t_1_1_2_2" align="left" valign="middle" rowspan="1" colspan="1">TD Type II</th>
                </tr>
                <tr>
                  <td headers="hd_b_td.T.molecular_genetic_testing_used_in_t_1_1_1_1" align="left" valign="middle" rowspan="3" colspan="1">
                    <italic toggle="yes">FGFR3</italic>
                  </td>
                  <td headers="hd_b_td.T.molecular_genetic_testing_used_in_t_1_1_1_2" align="left" valign="middle" rowspan="2" colspan="1">Targeted mutation analysis; sequence analysis of select regions</td>
                  <td headers="hd_b_td.T.molecular_genetic_testing_used_in_t_1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1">Reported mutations&#x000a0;<sup>4,&#x000a0;5</sup></td>
                  <td headers="hd_b_td.T.molecular_genetic_testing_used_in_t_1_1_1_4 hd_b_td.T.molecular_genetic_testing_used_in_t_1_1_2_1" align="left" valign="middle" rowspan="1" colspan="1">Up to 99%</td>
                  <td headers="hd_b_td.T.molecular_genetic_testing_used_in_t_1_1_1_4 hd_b_td.T.molecular_genetic_testing_used_in_t_1_1_2_2" align="left" valign="middle" rowspan="1" colspan="1">NA</td>
                </tr>
                <tr>
                  <td headers="hd_b_td.T.molecular_genetic_testing_used_in_t_1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1"><xref ref-type="table" rid="td.T.selected_fgfr3_allelic_variants">p.Lys650Glu</xref>
</td>
                  <td headers="hd_b_td.T.molecular_genetic_testing_used_in_t_1_1_1_4 hd_b_td.T.molecular_genetic_testing_used_in_t_1_1_2_1" align="left" valign="middle" rowspan="1" colspan="1">NA</td>
                  <td headers="hd_b_td.T.molecular_genetic_testing_used_in_t_1_1_1_4 hd_b_td.T.molecular_genetic_testing_used_in_t_1_1_2_2" align="left" valign="middle" rowspan="1" colspan="1">&#x0003e;99%</td>
                </tr>
                <tr>
                  <td headers="hd_b_td.T.molecular_genetic_testing_used_in_t_1_1_1_2" align="left" valign="middle" rowspan="1" colspan="1">Sequence analysis of entire coding region&#x000a0;<sup>6,</sup>&#x000a0;<sup>7</sup></td>
                  <td headers="hd_b_td.T.molecular_genetic_testing_used_in_t_1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">FGFR3</italic> sequence variants</td>
                  <td headers="hd_b_td.T.molecular_genetic_testing_used_in_t_1_1_1_4 hd_b_td.T.molecular_genetic_testing_used_in_t_1_1_2_1" align="left" valign="middle" rowspan="1" colspan="1">&#x0003e;99%</td>
                  <td headers="hd_b_td.T.molecular_genetic_testing_used_in_t_1_1_1_4 hd_b_td.T.molecular_genetic_testing_used_in_t_1_1_2_2" align="left" valign="middle" rowspan="1" colspan="1">&#x0003e;99%</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="td.TF.1">
                <p>NA = not applicable</p>
              </fn>
              <fn id="td.TF.1.1">
                <p>1. See <related-object source-id="gene" document-id="td" object-id="td.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
              </fn>
              <fn id="td.TF.1.2">
                <p>2. See <xref ref-type="sec" rid="td.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants. </p>
              </fn>
              <fn id="td.TF.1.3">
                <p>3. The ability of the test method used to detect a mutation that is present in the indicated gene</p>
              </fn>
              <fn id="td.TF.1.4">
                <p>4. Some labs do not test for <xref ref-type="table" rid="td.T.selected_fgfr3_allelic_variants">p.Lys650Met</xref>, the mutation that causes both <italic toggle="yes">s</italic>evere <italic toggle="yes">a</italic>chondroplasia with <italic toggle="yes">d</italic>evelopmental <italic toggle="yes">d</italic>elay and <italic toggle="yes">a</italic>canthosis <italic toggle="yes">n</italic>igricans (SADDAN) and thanatophoric dysplasia, type I [<xref ref-type="bibr" rid="td.REF.bellus.2000.1411">Bellus et al 2000</xref>].</p>
              </fn>
              <fn id="td.TF.1.5">
                <p>5. Mutation panels and detection rates may vary among laboratories. Selected exons of <italic toggle="yes">FGFR3</italic> previously reported to contain mutations; for TD type I, <italic toggle="yes">FGFR3</italic> exons 7, 10, 15, and 19; for TD type II, <italic toggle="yes">FGFR3</italic> exon 15.</p>
              </fn>
              <fn id="td.TF.1.6">
                <p>6. Not clinically indicated; see <xref ref-type="sec" rid="td.Molecular_Genetic_Testing">Molecular Genetic Testing</xref>, <bold>Sequence analysis of the entire <italic toggle="yes">FGFR3</italic> coding region</bold>.</p>
              </fn>
              <fn id="td.TF.1.7">
                <p>7. Examples of mutations detected by sequence analysis may include small intragenic deletions/insertions and missense, nonsense, and splice site mutations; typically, exonic or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
        </sec>
        <sec id="td.Testing_Strategy">
          <title>Testing Strategy</title>
          <p><bold>To confirm/establish the diagnosis</bold> when TD is suspected based on findings of pre- or postnatal examination:</p>
          <list list-type="bullet">
            <list-item>
              <p>If TD type II is suspected on the basis of straight femurs and cloverleaf skull, targeted testing for the <xref ref-type="table" rid="td.T.selected_fgfr3_allelic_variants">p.Lys650Glu</xref> mutation may be an appropriate first step in diagnostic testing.</p>
            </list-item>
            <list-item>
              <p>Otherwise, sequence analysis of select exons may considered, followed by full gene sequencing if no disease-causing mutation is identified. </p>
            </list-item>
          </list>
          <p><bold>Prenatal diagnosis</bold> for at-risk pregnancies requires prior identification of the disease-causing mutation in the family. </p>
          <p>Note: Some families with a previous child with confirmed TD may opt for molecular genetic testing (even though recurrence risk is not significantly elevated and ultrasound examination can detect TD early in pregnancy). </p>
        </sec>
      </sec>
      <sec id="td.Clinical_Description">
        <title>Clinical Characteristics</title>
        <sec id="td.Natural_History">
          <title>Clinical Description</title>
          <p>Thanatophoric dysplasia (TD) types I and II are diagnosed prenatally or in the immediate newborn period. Both subtypes are considered lethal skeletal dysplasias; most affected infants die of respiratory insufficiency in the first hours or days of life. Respiratory insufficiency may be secondary to a small chest cavity and lung hypoplasia, compression of the brain stem by the small foramen magnum, or a combination of both. Some affected children have survived into childhood with aggressive ventilatory support.</p>
          <sec id="td.Longterm_survivors">
            <title>Long-term survivors </title>
            <p>The clinical findings of two children (a male aged 4.75 years and a female aged 3.7 years at last follow up) were summarized by <xref ref-type="bibr" rid="td.REF.macdonald.1989.508">MacDonald et al [1989]</xref>. Both had birth length and weight below the third centile. Head circumference was at the 97th centile. In both, growth plateaued after age ten months:</p>
            <list list-type="bullet">
              <list-item>
                <p>The male required ventilatory support at birth and tracheostomy at age three months. Other clinical findings included: micromelia, redundant skin folds, hydrocephalus diagnosed at age two months, seizure activity at age three months, a small foramen magnum with compression of the brain stem diagnosed at age 15 months, and little developmental progress after age 20 months. Platyspondyly, bowed tubular bones, and splayed ribs were noted radiographically. Head CT showed abnormal differentiation of the white and grey matter of the brain.</p>
              </list-item>
              <list-item>
                <p>The female required ventilatory support beginning at age two months. A small foramen magnum with brain stem compression was diagnosed at age two months, and hydrocephaly was diagnosed at age four months. Bilateral hearing loss and progressive lack of ossification of the caudal spine were noted at age 3.7 years. She had two words and knew some sign language.</p>
              </list-item>
            </list>
            <p>A nine-year-old male with the common TD type I mutation <xref ref-type="table" rid="td.T.selected_fgfr3_allelic_variants">p.Arg248Cys</xref> was reported. Birth weight was at the 50th centile (normal growth charts); birth length was more than four SD below the mean (achondroplasia growth charts). He required tracheostomy and ventilatory support. At age three years, he demonstrated stable ventriculomegaly, craniosynostosis, and little limb growth. By age eight years, he had seizures, bilateral hearing loss, kyphosis, and both joint hypermobility and joint contractures. At age nine years, the limbs had grown little; and radiologic findings were similar to those expected in TD. Extensive acanthosis nigricans was present. He was severely developmentally delayed and had no language. Final height was estimated to be 80-90 cm (32-35 inches). </p>
            <p><xref ref-type="bibr" rid="td.REF.thompson.2011.92">Thompson et al [2011]</xref> described an 11-month (at time of publication) survivor who required suboccipital decompression in infancy due to clonus and decreased limb movements secondary to a narrow foramen magnum.</p>
            <p><bold>Mosaicism.</bold> A 47-year-old female mosaic for the common TD type I mutation p.Arg248Cys had asymmetric limb length, bilateral congenital hip dislocation, focal areas of bone bowing, an "S"-shaped humerus, extensive acanthosis nigricans, redundant skin folds along the length of the limbs, and flexion deformities of the knees and elbows [<xref ref-type="bibr" rid="td.REF.hyland.2003.157">Hyland et al 2003</xref>]. She had delayed developmental milestones as a child. Academic achievements were below those of healthy siblings, but she is able to read and write and is employed as a factory worker. Her only pregnancy ended with the stillbirth at 30 weeks' gestation of a male with a short-limb skeletal dysplasia and pulmonary hypoplasia.</p>
            <p><xref ref-type="bibr" rid="td.REF.takagi.2012.247">Takagi et al [2012]</xref> described an individual with somatic mosaicism for the <xref ref-type="table" rid="td.T.selected_fgfr3_allelic_variants">p.Arg248Cys</xref> substitution in <italic toggle="yes">FGFR3</italic> (a mutation which typically results in TD type I) who presented with features of atypical achondroplasia. </p>
          </sec>
        </sec>
        <sec id="td.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>TD types I and II do not share common <italic toggle="yes">FGFR3</italic> mutations [<xref ref-type="bibr" rid="td.REF.wilcox.1998.274">Wilcox et al 1998</xref>, <xref ref-type="bibr" rid="td.REF.brodie.1999.476">Brodie et al 1999</xref>, <xref ref-type="bibr" rid="td.REF.camera.2001.277">Camera et al 2001</xref>]. </p>
          <p>No strong genotype-phenotype correlation for <italic toggle="yes">FGFR3</italic> mutations exists within TD type I and TD type II, respectively. Variability in the TD phenotype has been described and, with the exception of the proposed mutation-dependent differences in severity of endochondral disturbance in the long bones [<xref ref-type="bibr" rid="td.REF.bellus.2000.1411">Bellus et al 2000</xref>], is not mutation specific.</p>
          <p>Cases of TD caused by two <italic toggle="yes">FGFR3</italic> mutations in <italic toggle="yes">cis</italic> have been reported [<xref ref-type="bibr" rid="td.REF.pannier.2009.1296">Pannier et al 2009</xref>, <xref ref-type="bibr" rid="td.REF.marquisnicholson.2013.80">Marquis-Nicholson et al 2013</xref>]. In both cases one mutation was previously reported to be associated with hypochondroplasia and one was a novel missense mutation. </p>
          <p>Other clinical disorders rarely involve <italic toggle="yes">FGFR3</italic> mutations previously identified in individuals with TD (see <xref ref-type="sec" rid="td.Genetically_Related_Allelic_Disorders">Genetically Related Disorders</xref>).</p>
        </sec>
        <sec id="td.Penetrance">
          <title>Penetrance</title>
          <p>The penetrance of mutations in <italic toggle="yes">FGFR3</italic> is 100%.</p>
        </sec>
        <sec id="td.Anticipation">
          <title>Anticipation</title>
          <p>Anticipation is not observed.</p>
        </sec>
        <sec id="td.Nomenclature">
          <title>Nomenclature</title>
          <p>TD was originally described as thanatophoric dwarfism, a term no longer in use.</p>
          <p>Although considered to be one of the platyspondylic lethal skeletal dysplasias, the term PLSD used with a specific subtype (San Diego, Luton, or Torrance) would be considered a separate clinical entity from TD types I and II. The PLSDs are sometimes referred to as "TD variants" because of their clinical similarity.</p>
        </sec>
        <sec id="td.Prevalence">
          <title>Prevalence</title>
          <p>The incidence of TD was originally estimated at 1:20,000 to 1:50,000 births [<xref ref-type="bibr" rid="td.REF.wilcox.1998.274">Wilcox et al 1998</xref>, <xref ref-type="bibr" rid="td.REF.baitner.2000.594">Baitner et al 2000</xref>, <xref ref-type="bibr" rid="td.REF.chen.2001.89">Chen et al 2001</xref>]. Recent studies suggest that the incidence is actually closer to 1:20,000 [<xref ref-type="bibr" rid="td.REF.barbosabuck.2012.1038">Barbosa-Buck et al 2012</xref>] or higher (1:12,000 in Northern Ireland) in a population with optimized ascertainment [<xref ref-type="bibr" rid="td.REF.donnelly.2010.114">Donnelly et al 2010</xref>].</p>
        </sec>
      </sec>
      <sec id="td.Genetically_Related_Allelic_Disorders">
        <title>Genetically Related (Allelic) Disorders</title>
        <p><italic toggle="yes">FGFR3</italic> mutations have been identified in several disorders with highly variable phenotypes:</p>
        <list list-type="bullet">
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="achondroplasia" document-type="chapter"><bold>Achondroplasia</bold></related-object>. The causative <italic toggle="yes">FGFR3</italic> mutations p.Gly380Arg and p.Gly375Cys have been identified in nearly 100% of individuals [<xref ref-type="bibr" rid="td.REF.camera.2001.277">Camera et al 2001</xref>]. <xref ref-type="bibr" rid="td.REF.camera.2001.277">Camera et al [2001]</xref> reported an individual with the common TD type I mutation p.Arg248Cys and a clinical phenotype of achondroplasia. Although mosaicism remains a possible explanation for the mild phenotype, no mosaicism was identified in either buccal mucosal cells or blood.</p>
          </list-item>
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="hypochondroplasia" document-type="chapter"><bold>Hypochondroplasia</bold></related-object>. Although <italic toggle="yes">FGFR3</italic> mutations are identifiable in about 80% of individuals with hypochondroplasia, several families are not linked to <italic toggle="yes">FGFR3</italic>; therefore, genetic heterogeneity is likely [<xref ref-type="bibr" rid="td.REF.camera.2001.277">Camera et al 2001</xref>].</p>
          </list-item>
          <list-item>
            <p><bold>SADDAN</bold> (<italic toggle="yes">s</italic>evere <italic toggle="yes">a</italic>chondroplasia with <italic toggle="yes">d</italic>evelopmental <italic toggle="yes">d</italic>elay and <italic toggle="yes">a</italic>canthosis <italic toggle="yes">n</italic>igricans) is caused by <italic toggle="yes">FGFR3</italic> mutation p.Lys650Met [<xref ref-type="bibr" rid="td.REF.bellus.1999.53">Bellus et al 1999</xref>, <xref ref-type="bibr" rid="td.REF.tavormina.1999.722">Tavormina et al 1999</xref>].</p>
          </list-item>
          <list-item>
            <p><bold>Crouzon syndrome with acanthosis nigricans</bold> (see <related-object link-type="booklink" source-id="gene" document-id="craniosynostosis" document-type="chapter"><italic toggle="yes">FGFR</italic>-Related Craniosynostosis Syndromes</related-object>) is caused by <italic toggle="yes">FGFR3</italic> mutation p.Ala391Glu.</p>
          </list-item>
          <list-item>
            <p><bold>Familial acanthosis nigricans.</bold> A p.Lys650Thr mutation was identified in several affected family members with autosomal dominant acanthosis nigricans and short stature. </p>
          </list-item>
          <list-item>
            <p><bold>Nonsyndromic coronal synostosis</bold> (<related-object link-type="booklink" source-id="gene" document-id="muenke" document-type="chapter">Muenke syndrome</related-object>) (see also <related-object link-type="booklink" source-id="gene" document-id="craniosynostosis" document-type="chapter"><italic toggle="yes">FGFR</italic>-Related Craniosynostosis Syndromes</related-object>) is characterized by a p.Pro250Arg mutation in <italic toggle="yes">FGFR3</italic> [<xref ref-type="bibr" rid="td.REF.passosbueno.1999.115">Passos-Bueno et al 1999</xref>, <xref ref-type="bibr" rid="td.REF.mcintosh.2000.85">McIntosh et al 2000</xref>].</p>
          </list-item>
          <list-item>
            <p><bold>Platyspondylic lethal skeletal dysplasia, San Diego type (PLSD-SD).</bold> Although PLSD-SD has been described as a distinct clinical entity, much phenotypic overlap exists with TD. Both disorders feature short, bowed long bones, platyspondyly, and short ribs. In PLSD-SD, metaphyseal flaring and chondrocyte abnormalities can be less severe [<xref ref-type="bibr" rid="td.REF.brodie.1999.476">Brodie et al 1999</xref>]. An important histologic difference is the consistent presence in the chondrocytes in PLSD-SD of dilated loops/inclusion bodies in the endoplasmic reticulum, which are not typical in TD. All individuals with PLSD-SD studied by <xref ref-type="bibr" rid="td.REF.brodie.1999.476">Brodie et al [1999]</xref> had <italic toggle="yes">FGFR3</italic> mutations previously reported in association with TD type I.</p>
          </list-item>
          <list-item>
            <p><bold>LADD syndrome</bold> (<italic toggle="yes">l</italic>acrimo-<italic toggle="yes">a</italic>uriculo-<italic toggle="yes">d</italic>ento-<italic toggle="yes">d</italic>igital syndrome, Levy Hollister syndrome). <italic toggle="yes">FGFR3</italic> mutation p.Asp513Asn has been reported in one family with this syndrome [<xref ref-type="bibr" rid="td.REF.rohmann.2006.414">Rohmann et al 2006</xref>].</p>
          </list-item>
        </list>
      </sec>
      <sec id="td.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Disorders to consider in the differential diagnosis of thanatophoric dysplasia (TD) [<xref ref-type="bibr" rid="td.REF.passosbueno.1999.115">Passos-Bueno et al 1999</xref>, <xref ref-type="bibr" rid="td.REF.debiasio.2000.835">De Biasio et al 2000</xref>, <xref ref-type="bibr" rid="td.REF.lee.2002.113">Lee et al 2002</xref>, <xref ref-type="bibr" rid="td.REF.neumann.2003.786">Neumann et al 2003</xref>]:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Homozygous</bold>
<related-object link-type="booklink" source-id="gene" document-id="achondroplasia" document-type="chapter"><bold>achondroplasia</bold></related-object> has a similar clinical presentation and should be a part of the differential diagnosis when both parents have achondroplasia.</p>
          </list-item>
          <list-item>
            <p><bold>Achondrogenesis,</bold> including <bold>achondrogenesis type IA,</bold>
<related-object link-type="booklink" source-id="gene" document-id="achon1b" document-type="chapter"><bold>type IB</bold></related-object><bold>,</bold> and <bold>type II, Schneckenbecken dysplasia.</bold> Clinical features of achondrogenesis type 1B (ACG1B) include extremely short limbs with short fingers and toes, hypoplasia of the thorax, protuberant abdomen, and hydropic fetal appearance caused by the abundance of soft tissue relative to the short skeleton. The face is flat, the neck is short, and the soft tissue of the neck may be thickened. The vertebral bodies show no or minimal ossification. The ribs are short. The iliac bones are ossified only in their upper part, giving a crescent-shaped, "paraglider-like" appearance on x-ray. The ischia are usually not ossified. The tubular bones are shortened such that no major axis can be recognized; metaphyseal spurring gives the appearance of a "thorn apple." The phalanges are poorly ossified and therefore only rarely identified in x-rays. Death occurs prenatally or shortly after birth. The final diagnosis should be based on molecular genetic testing of <italic toggle="yes">SLC26A2</italic> (<italic toggle="yes">DTDST</italic>). The presence of rib fractures and the absence of ossification of vertebral pedicles may suggest ACG1A. ACG2 shows more severe underossification of the vertebral bodies than ACG1B, in addition to quite typical configuration of the iliac bones with concave medial and inferior borders, and non-ossification of the ischial and pubic bones. The gene in which mutations occur to cause ACG1A is <italic toggle="yes">TRIP11</italic>; ACG2 is caused by <italic toggle="yes">COL2A1</italic> mutations.</p>
          </list-item>
          <list-item>
            <p><bold>SADDAN (severe achondroplasia with developmental delay and acanthosis nigricans)</bold> (see <related-object link-type="booklink" source-id="gene" document-id="achondroplasia" document-type="chapter">Achondroplasia</related-object>) is a rare disorder characterized by extremely short stature, severe tibial bowing, profound developmental delay, and acanthosis nigricans. Unlike individuals with TD, those with SADDAN dysplasia survive past infancy. The three unrelated individuals with this phenotype who have been observed to date have had obstructive apnea but have not required prolonged mechanical ventilation. An <italic toggle="yes">FGFR3</italic> p.Lys650Met mutation has been identified in all three individuals.</p>
          </list-item>
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="oi" document-type="chapter"><bold>Osteogenesis imperfecta</bold></related-object>
<bold>type II (OI type II).</bold> Osteogenesis imperfecta (OI) is characterized by fractures with minimal or absent trauma. Clinically, OI was classified into four types; the type most reminiscent of TD is OI type II (the perinatal lethal form). This disorder is characterized by extremely short stature, dark blue sclerae, severe limb deformity, multiple fractures of ribs, minimal calvarial mineralization, platyspondyly, and marked compression of long bones. Biochemical testing (i.e., analysis of the structure and quantity of type I collagen synthesized in vitro by cultured dermal fibroblasts) detects abnormalities in 98% of individuals with OI type II. Most individuals with OI type II have mutations in either <italic toggle="yes">COL1A1</italic> or <italic toggle="yes">COL1A2</italic>, the two genes encoding type I collagen. Osteogenesis imperfecta type II is inherited in an autosomal dominant manner.</p>
          </list-item>
          <list-item>
            <p><bold>Short rib-polydactyly syndromes</bold> are short-limb dwarfisms with narrow thorax. They are currently classified into four subtypes that may or may not be proven to be distinct clinical entities. Findings distinguishing these disorders from TD include polydactyly and/or syndactyly of the hands or feet. Type I (Saldino-Noonan type) features cardiac defects. Type II (Majewski type) may have cleft lip, cleft palate, ambiguous genitalia, and renal abnormalities. Inheritance is autosomal recessive.</p>
          </list-item>
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="campo-dysp" document-type="chapter"><bold>Campomelic dysplasia</bold></related-object>
<bold>(CD)</bold> is a prenatal-onset, usually lethal skeletal dysplasia with narrow thorax. Individuals with CD have bowed tibiae, skin dimples, and hypoplastic scapulae. Many individuals with CD have 11 pairs of ribs. The tubular bones are poorly developed and show immature ossification. <xref ref-type="bibr" rid="td.REF.mansour.1995.415">Mansour et al [1995]</xref> found that up to 75% of individuals with CD with a 46,XY karyotype have either female external genitalia or ambiguous genitalia. Campomelic dysplasia is caused by <italic toggle="yes">de novo</italic>, autosomal dominant mutations in <italic toggle="yes">SOX9</italic> or chromosomal rearrangements upstream or downstream of <italic toggle="yes">SOX9</italic> on chromosome 17. </p>
          </list-item>
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="rcdp" document-type="chapter"><bold>Rhizomelic chondrodysplasia punctata</bold></related-object>
<bold>(RCDP)</bold> is a disorder of peroxisome biogenesis. Type 1 (RCDP1), the classic type, is characterized by rhizomelia (shortening of the humerus and to a lesser degree the femur), punctate calcifications in cartilage with epiphyseal and metaphyseal abnormalities (chondrodysplasia punctata), coronal clefts of the vertebral bodies, and cataracts that are usually present at birth or appear in the first few months of life. Birth weight, length, and head circumference are often at the lower range of normal; postnatal growth deficiency is profound. Intellectual disability is severe, and the majority of children develop seizures. Most affected children do not survive the first decade of life; a proportion die in the neonatal period. The diagnosis of RCDP1 is confirmed by the demonstration of deficiency of red blood cell plasmalogens, increased plasma concentration of phytanic acid, and deficiencies in plasmalogen biosynthesis and phytanic acid oxidation in cultured skin fibroblasts. The disorder is caused by mutations in <italic toggle="yes">PEX7</italic>, the gene encoding the receptor for a subset of peroxisomal matrix enzymes. A common mutation is responsible in the majority. Inheritance is autosomal recessive. </p>
          </list-item>
          <list-item>
            <p><bold>Asphyxiating thoracic dystrophy (Jeune thoracic dystrophy)</bold> is another chondrodysplasia marked by a narrow thorax. Short stature and short limbs are noted in infancy, but survivors may manifest only mild-to-moderate short stature. Survivors commonly develop renal insufficiency and can develop liver disease. Inheritance is autosomal recessive.</p>
          </list-item>
          <list-item>
            <p><bold>Platyspondylic lethal skeletal dysplasia (PLSD) &#x02014; San Diego type, Torrance type, and Luton type.</bold> These short-limb dwarfism syndromes are clinically very similar to TD and have often been referred to as "TD variants." The Luton type is considered to be a mild form of the Torrance type [<xref ref-type="bibr" rid="td.REF.nishimura.2004.75">Nishimura et al 2004</xref>]. PLSD, Torrance type is characterized by shortened long bones with ragged metaphyses, radial bowing, and wafer-like vertebrae. All subtypes can be distinguished from TD histologically by the consistent presence of dilated loops of endoplasmic reticulum in the chondrocytes. <italic toggle="yes">FGFR3</italic> mutations have been identified in PLSD, San Diego type, but not in Torrance or Luton types [<xref ref-type="bibr" rid="td.REF.brodie.1999.476">Brodie et al 1999</xref>, <xref ref-type="bibr" rid="td.REF.neumann.2003.786">Neumann et al 2003</xref>]. <xref ref-type="bibr" rid="td.REF.nishimura.2004.75">Nishimura et al [2004]</xref> and <xref ref-type="bibr" rid="td.REF.zankl.2005.61">Zankl et al [2005]</xref> identified <italic toggle="yes">COL2A1</italic> mutations in several families with PLSD, Torrance type or PLSD, Torrance-Luton type. </p>
          </list-item>
          <list-item>
            <p><bold>Dyssegmental dysplasia, Silverman-Handmaker type (DDSH)</bold> is a lethal disorder characterized by narrow thorax, short neck, short stature, bowed limbs, and irregular ossification of the vertebral bodies. Encephalocele and cleft palate are common. DDSH is caused by mutations in the heparan sulfate proteoglycan gene, <italic toggle="yes">HSPG2</italic> [<xref ref-type="bibr" rid="td.REF.arikawahirasawa.2001.254">Arikawa-Hirasawa et al 2001</xref>]. Inheritance is autosomal recessive.</p>
          </list-item>
        </list>
      </sec>
      <sec id="td.Management">
        <title>Management</title>
        <sec id="td.Evaluations_Following_Initial_Diagnos">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease and needs in a newborn diagnosed with thanatophoric dysplasia (TD), the following evaluations are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>Assessment of respiratory status by respiratory rate and skin color; arterial blood gases may be helpful in infants who survive the immediate postnatal period.</p>
            </list-item>
            <list-item>
              <p>Assessment of the presence of hydrocephaly or other central nervous system abnormalities by CT or MRI</p>
            </list-item>
            <list-item>
              <p>Medical genetics consultation and genetic counseling</p>
            </list-item>
          </list>
        </sec>
        <sec id="td.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>Management concerns are limited to the parents' desire for extreme life-support measures and provision-of-comfort care for the newborn.</p>
          <p>Newborns require respiratory support (with tracheostomy and ventilation) to survive.</p>
          <p>Anesthesia management concerns are described by <xref ref-type="bibr" rid="td.REF.thompson.2011.92">Thompson et al [2011]</xref> and include:</p>
          <list list-type="bullet">
            <list-item>
              <p>Intubation with the cervical spine in a neutral position using a flexible fiber-optic scope</p>
            </list-item>
            <list-item>
              <p>Utilization of evoked potential monitoring (somatosensory evoked potentials [SEPs] and motor evoked potentials [MEPs]) during the procedure to evaluate safety during intraoperative manipulations</p>
            </list-item>
            <list-item>
              <p>Avoidance of volatile anesthetic agents and muscle relaxants which could affect the evoked potential recordings </p>
            </list-item>
          </list>
          <p>Other measures:</p>
          <list list-type="bullet">
            <list-item>
              <p>Medication to control seizures, as in the general population</p>
            </list-item>
            <list-item>
              <p>Shunt placement, when hydrocephaly is identified</p>
            </list-item>
            <list-item>
              <p>Suboccipital decompression for relief of craniocervical junction constriction</p>
            </list-item>
            <list-item>
              <p>Hearing aids, when hearing loss is identified</p>
            </list-item>
          </list>
        </sec>
        <sec id="td.Surveillance">
          <title>Surveillance</title>
          <p>The following are appropriate:</p>
          <list list-type="bullet">
            <list-item>
              <p>Routine assessment of neurologic status on physical examination</p>
            </list-item>
            <list-item>
              <p>Orthopedic evaluation upon the development of joint contractures or joint hypermobility [<xref ref-type="bibr" rid="td.REF.wilcox.1998.274">Wilcox et al 1998</xref>] </p>
            </list-item>
            <list-item>
              <p>Audiology assessment</p>
            </list-item>
            <list-item>
              <p>CT to evaluate for craniocervical constriction in long-term survivors if respiratory insufficiency is potentially the result of compression of the brain stem at the craniocervical junction </p>
            </list-item>
            <list-item>
              <p>EEG for seizure activity</p>
            </list-item>
          </list>
        </sec>
        <sec id="td.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>See <xref ref-type="sec" rid="td.Related_Genetic_Counseling_Issues">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="td.Pregnancy_Management">
          <title>Pregnancy Management </title>
          <p>When TD has been diagnosed prenatally, potential pregnancy complications include prematurity, polyhydramnios, malpresentation, and cephalopelvic disproportion caused by macrocephaly from hydrocephalus or a flexed and rigid neck. Cephalocentesis and cesarean section may be considered to avoid maternal complications.</p>
          <p>Management of an affected pregnancy is directed by the level of parental desire for heroic life-saving measures and is often highly center-specific. It can be addressed on three levels:</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Maternal.</bold> Surveillance for cephalopelvic disproportion, polyhydramnios, and/or preterm labor; avoidance of emergency C-section for fetal distress</p>
            </list-item>
            <list-item>
              <p><bold>Fetal.</bold> Surveillance for malpresentation, periodic prenatal ultrasound monitoring of head circumference, MRI for fetal lung volume, and/or fetal stress testing</p>
            </list-item>
            <list-item>
              <p><bold>Familial.</bold> Establishment of a perinatal plan for assessment, care, and/or withdrawal of care after delivery</p>
            </list-item>
          </list>
        </sec>
        <sec id="td.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p>
        </sec>
      </sec>
      <sec id="td.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="td.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>Thanatophoric dysplasia (TD) is inherited in an autosomal dominant manner; the majority of probands have a <italic toggle="yes">de novo</italic> mutation.</p>
        </sec>
        <sec id="td.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>TD is almost always caused by a <italic toggle="yes">de novo</italic> mutation in <italic toggle="yes">FGFR3</italic>.</p>
            </list-item>
            <list-item>
              <p>Parents of a proband are not affected.</p>
            </list-item>
            <list-item>
              <p>Somatic mosaicism that included the germline mutation in <italic toggle="yes">FGFR3</italic> (<xref ref-type="table" rid="td.T.selected_fgfr3_allelic_variants">p.Arg248Cys</xref>) has been reported in an affected individual [<xref ref-type="bibr" rid="td.REF.hyland.2003.157">Hyland et al 2003</xref>]; this individual's only offspring had a lethal skeletal dysplasia. Current diagnostic techniques do not detect mosaicism for <italic toggle="yes">FGFR3</italic> mutations causing TD. </p>
            </list-item>
            <list-item>
              <p>An advanced paternal age effect has been reported [<xref ref-type="bibr" rid="td.REF.lemyre.1999.185">Lemyre et al 1999</xref>, <xref ref-type="bibr" rid="td.REF.donnelly.2010.114">Donnelly et al 2010</xref>].</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The risk to the sibs of the proband depends on the genetic status of the proband's parents.</p>
            </list-item>
            <list-item>
              <p>Because TD generally occurs as the result of a <italic toggle="yes">de novo</italic> mutation, the risk to the sibs of a proband is small.</p>
            </list-item>
            <list-item>
              <p>Although no instances of germline mosaicism in an individual without signs of a skeletal dysplasia have been reported in the literature, it remains a theoretic possibility. </p>
            </list-item>
          </list>
          <p>
            <bold>Offspring of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Individuals with TD do not reproduce.</p>
            </list-item>
            <list-item>
              <p>Somatic and germline mosaicism for a mutation in <italic toggle="yes">FGFR3</italic> (p.Arg248Cys) has been reported in an affected individual [<xref ref-type="bibr" rid="td.REF.hyland.2003.157">Hyland et al 2003</xref>]; this individual's only offspring had a lethal skeletal dysplasia.</p>
            </list-item>
          </list>
          <p><bold>Other family members of a proband.</bold> Extended family members of the proband are not at increased risk.</p>
        </sec>
        <sec id="td.Related_Genetic_Counseling_Issues">
          <title>Related Genetic Counseling Issues</title>
          <p><bold>Family planning.</bold> The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy. </p>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals. </p>
        </sec>
        <sec id="td.Prenatal_Testing">
          <title>Prenatal Testing</title>
          <p><bold>High-risk pregnancies.</bold> If the disease-causing mutation has been identified in an affected family member, prenatal testing for pregnancies at increased risk is possible either through a clinical laboratory or a laboratory offering custom prenatal testing.</p>
          <p><bold>Low-risk pregnancies.</bold> Routine prenatal ultrasound examination may identify skeletal findings (e.g., cloverleaf skull, very short extremities, small thorax) that raise the possible diagnosis of TD in a fetus not known to be at risk. Once a lethal skeletal dysplasia is identified prenatally, it is often difficult to pinpoint a specific diagnosis. Consideration of molecular genetic testing for <italic toggle="yes">FGFR3</italic> mutations in these situations is appropriate.</p>
          <p><bold>Preimplantation genetic diagnosis (PGD)</bold> may be an option for some families in which the disease-causing mutation has been identified. </p>
        </sec>
      </sec>
      <sec id="td.Resources">
        <title>Resources</title>
      </sec>
      <sec id="td.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <p><bold>Gene structure.</bold>
<italic toggle="yes">FGFR3</italic> is 17 exons in length with transcription initiation located in exon 2. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="td" object-id="td.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
        <p><bold>Benign allelic variants.</bold> See <xref ref-type="table" rid="td.T.selected_fgfr3_allelic_variants">Table 2</xref> for known normal variants.</p>
        <p>
          <bold>Pathogenic allelic variants</bold>
        </p>
        <list list-type="bullet">
          <list-item>
            <p><bold>TD type I.</bold>
<italic toggle="yes">FGFR3</italic> mutations responsible for the TD type I phenotype can be divided into two categories:</p>
            <list list-type="bullet">
              <list-item>
                <p><bold>Missense mutations</bold> [<xref ref-type="bibr" rid="td.REF.passosbueno.1999.115">Passos-Bueno et al 1999</xref>]. Most of these mutations create new, unpaired cysteine residues in the protein. The two common mutations p.Arg248Cys and p.Tyr373Cys probably account for 60%-80% of TD type I (see <xref ref-type="table" rid="td.T.selected_fgfr3_allelic_variants">Table 2</xref>).</p>
              </list-item>
              <list-item>
                <p><bold>Stop codon mutations.</bold> These mutations cause a read-through of the native stop codon, adding a highly hydrophobic alpha helix-containing domain to the C terminus of the protein. Mutations that obliterate the stop codon represent 10% or more of TD type I mutations (see <xref ref-type="table" rid="td.T.selected_fgfr3_allelic_variants">Table 2</xref>).</p>
              </list-item>
            </list>
          </list-item>
          <list-item>
            <p><bold>TD type II.</bold> A single <italic toggle="yes">FGFR3</italic> mutation (p.Lys650Glu) has been identified in all cases of TD type II [<xref ref-type="bibr" rid="td.REF.bellus.2000.1411">Bellus et al 2000</xref>]. The lysine residue at position 650 plays a role in stabilizing the activation loop of the tyrosine kinase domain in an inactive state. Mutations of this residue destabilize the loop, allowing ligand-independent activation of the tyrosine kinase domain, likely without the need for receptor dimerization at the cell surface [<xref ref-type="bibr" rid="td.REF.bellus.2000.1411">Bellus et al 2000</xref>]. Other mutations at this position give rise to different phenotypes: p.Lys650Met has been identified in TD type I, and p.Lys650Gln is seen in SADDAN (see <xref ref-type="table" rid="td.T.selected_fgfr3_allelic_variants">Table 2</xref>).</p>
          </list-item>
        </list>
        <table-wrap id="td.T.selected_fgfr3_allelic_variants" position="anchor" orientation="portrait">
          <label>Table 2.</label>
          <caption>
            <p>Selected <italic toggle="yes">FGFR3</italic> Allelic Variants </p>
          </caption>
          <table>
            <tbody>
              <tr>
                <th id="hd_b_td.T.selected_fgfr3_allelic_variants_1_1_1_1" align="left" valign="middle" rowspan="1" colspan="1">Phenotype</th>
                <th id="hd_b_td.T.selected_fgfr3_allelic_variants_1_1_1_2" align="left" valign="middle" rowspan="1" colspan="1">Class of Variant Allele</th>
                <th id="hd_b_td.T.selected_fgfr3_allelic_variants_1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1">DNA Nucleotide Change</th>
                <th id="hd_b_td.T.selected_fgfr3_allelic_variants_1_1_1_4" align="left" valign="middle" rowspan="1" colspan="1">Protein Amino Acid Change<break/>(Alias&#x000a0;<sup>1</sup>)</th>
                <th id="hd_b_td.T.selected_fgfr3_allelic_variants_1_1_1_5" align="left" valign="middle" rowspan="1" colspan="1">Reference Sequences</th>
              </tr>
              <tr>
                <td headers="hd_b_td.T.selected_fgfr3_allelic_variants_1_1_1_1" align="left" valign="middle" rowspan="2" colspan="1">Not applicable</td>
                <td headers="hd_b_td.T.selected_fgfr3_allelic_variants_1_1_1_2" align="left" valign="middle" rowspan="2" colspan="1">Benign</td>
                <td headers="hd_b_td.T.selected_fgfr3_allelic_variants_1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1">c.882C&#x0003e;T</td>
                <td headers="hd_b_td.T.selected_fgfr3_allelic_variants_1_1_1_4" align="left" valign="middle" rowspan="1" colspan="1">p.(=)&#x000a0;<sup>2</sup>
<break/>(N294N)</td>
                <td headers="hd_b_td.T.selected_fgfr3_allelic_variants_1_1_1_5" align="left" valign="middle" rowspan="16" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=NM_000142.3">NM_000142.3</ext-link>
                  <break/>
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=NP_000133.1">NP_000133.1</ext-link>
                </td>
              </tr>
              <tr>
                <td headers="hd_b_td.T.selected_fgfr3_allelic_variants_1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1">c.1953A&#x0003e;G</td>
                <td headers="hd_b_td.T.selected_fgfr3_allelic_variants_1_1_1_4" align="left" valign="middle" rowspan="1" colspan="1">p.(=) <break/>(T651T)</td>
              </tr>
              <tr>
                <td headers="hd_b_td.T.selected_fgfr3_allelic_variants_1_1_1_1" align="left" valign="middle" rowspan="13" colspan="1">TD type I</td>
                <td headers="hd_b_td.T.selected_fgfr3_allelic_variants_1_1_1_2" align="left" valign="middle" rowspan="14" colspan="1">Pathogenic</td>
                <td headers="hd_b_td.T.selected_fgfr3_allelic_variants_1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1">c.742C&#x0003e;T</td>
                <td headers="hd_b_td.T.selected_fgfr3_allelic_variants_1_1_1_4" align="left" valign="middle" rowspan="1" colspan="1">p.Arg248Cys&#x000a0;<sup>3</sup></td>
              </tr>
              <tr>
                <td headers="hd_b_td.T.selected_fgfr3_allelic_variants_1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1">c.746C&#x0003e;G</td>
                <td headers="hd_b_td.T.selected_fgfr3_allelic_variants_1_1_1_4" align="left" valign="middle" rowspan="1" colspan="1">p.Ser249Cys</td>
              </tr>
              <tr>
                <td headers="hd_b_td.T.selected_fgfr3_allelic_variants_1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1">c.1108G&#x0003e;T</td>
                <td headers="hd_b_td.T.selected_fgfr3_allelic_variants_1_1_1_4" align="left" valign="middle" rowspan="1" colspan="1">p.Gly370Cys</td>
              </tr>
              <tr>
                <td headers="hd_b_td.T.selected_fgfr3_allelic_variants_1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1">c.1111A&#x0003e;T</td>
                <td headers="hd_b_td.T.selected_fgfr3_allelic_variants_1_1_1_4" align="left" valign="middle" rowspan="1" colspan="1">p.Ser371Cys</td>
              </tr>
              <tr>
                <td headers="hd_b_td.T.selected_fgfr3_allelic_variants_1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1">c.1118A&#x0003e;G</td>
                <td headers="hd_b_td.T.selected_fgfr3_allelic_variants_1_1_1_4" align="left" valign="middle" rowspan="1" colspan="1">p.Tyr373Cys&#x000a0;<sup>3</sup></td>
              </tr>
              <tr>
                <td headers="hd_b_td.T.selected_fgfr3_allelic_variants_1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1">c.1949A&#x0003e;T</td>
                <td headers="hd_b_td.T.selected_fgfr3_allelic_variants_1_1_1_4" align="left" valign="middle" rowspan="1" colspan="1">p.Lys650Met</td>
              </tr>
              <tr>
                <td headers="hd_b_td.T.selected_fgfr3_allelic_variants_1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1">c.2420G&#x0003e;T</td>
                <td headers="hd_b_td.T.selected_fgfr3_allelic_variants_1_1_1_4" align="left" valign="middle" rowspan="1" colspan="1">p.Ter807LeuextTer101</td>
              </tr>
              <tr>
                <td headers="hd_b_td.T.selected_fgfr3_allelic_variants_1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1">c.2419T&#x0003e;G</td>
                <td headers="hd_b_td.T.selected_fgfr3_allelic_variants_1_1_1_4" align="left" valign="middle" rowspan="1" colspan="1">p.Ter807GlyextTer101</td>
              </tr>
              <tr>
                <td headers="hd_b_td.T.selected_fgfr3_allelic_variants_1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1">c.2419T&#x0003e;C</td>
                <td headers="hd_b_td.T.selected_fgfr3_allelic_variants_1_1_1_4" align="left" valign="middle" rowspan="1" colspan="1">p.Ter807ArgextTer101</td>
              </tr>
              <tr>
                <td headers="hd_b_td.T.selected_fgfr3_allelic_variants_1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1">c.2419T&#x0003e;A</td>
                <td headers="hd_b_td.T.selected_fgfr3_allelic_variants_1_1_1_4" align="left" valign="middle" rowspan="1" colspan="1">p.Ter807ArgextTer101</td>
              </tr>
              <tr>
                <td headers="hd_b_td.T.selected_fgfr3_allelic_variants_1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1">c.2421A&#x0003e;T</td>
                <td headers="hd_b_td.T.selected_fgfr3_allelic_variants_1_1_1_4" align="left" valign="middle" rowspan="1" colspan="1">p.Ter807CysextTer101</td>
              </tr>
              <tr>
                <td headers="hd_b_td.T.selected_fgfr3_allelic_variants_1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1">c.2421A&#x0003e;C</td>
                <td headers="hd_b_td.T.selected_fgfr3_allelic_variants_1_1_1_4" align="left" valign="middle" rowspan="1" colspan="1">p.Ter807CysextTer101</td>
              </tr>
              <tr>
                <td headers="hd_b_td.T.selected_fgfr3_allelic_variants_1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1">c.2421A&#x0003e;G</td>
                <td headers="hd_b_td.T.selected_fgfr3_allelic_variants_1_1_1_4" align="left" valign="middle" rowspan="1" colspan="1">p.Ter807TrpextTer101</td>
              </tr>
              <tr>
                <td headers="hd_b_td.T.selected_fgfr3_allelic_variants_1_1_1_1" align="left" valign="middle" rowspan="1" colspan="1">TD type II</td>
                <td headers="hd_b_td.T.selected_fgfr3_allelic_variants_1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1">c.1948A&#x0003e;G</td>
                <td headers="hd_b_td.T.selected_fgfr3_allelic_variants_1_1_1_4" align="left" valign="middle" rowspan="1" colspan="1">p.Lys650Glu</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="td.TF.2">
              <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants. </p>
            </fn>
            <fn id="td.TF.2.1">
              <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature. </p>
            </fn>
            <fn id="td.TF.2.2">
              <p>1. Variant designation that does not conform to current naming conventions </p>
            </fn>
            <fn id="td.TF.2.3">
              <p>2. p.(=) indicates that the protein has not been analyzed but no change is expected.</p>
            </fn>
            <fn id="td.TF.2.4">
              <p>3. Two most common mutations</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p><bold>Normal gene product.</bold>
<italic toggle="yes">FGFR3</italic> encodes one of four known fibroblast growth factor receptors (FGFRs). All FGFRs share considerable amino acid homology, and the genomic organization is nearly identical to that seen in mice. FGFRs are proteoglycans that function as tyrosine kinases upon binding of a ligand &#x02014; usually one of more than 20 fibroblast growth factors (FGFs) plus proteoglycans containing heparan sulfate [<xref ref-type="bibr" rid="td.REF.mcintosh.2000.85">McIntosh et al 2000</xref>, <xref ref-type="bibr" rid="td.REF.torley.2002.1096">Torley et al 2002</xref>, <xref ref-type="bibr" rid="td.REF.lievens.2003.17344">Lievens &#x00026; Liboi 2003</xref>]. Once a ligand binds, the FGFRs form homo- or heterodimers and undergo phosphorylation of the tyrosine residues in the tyrosine kinase domain. This is followed by a conformational change that frees intracellular binding sites. Intracellular proteins bind and initiate a signal cascade that usually influences protein activation or gene expression [<xref ref-type="bibr" rid="td.REF.cohen.2002.304">Cohen 2002</xref>, <xref ref-type="bibr" rid="td.REF.torley.2002.1096">Torley et al 2002</xref>]. Multiple pathways have been implicated, including ras/MAPK/ERK, P13/Akt, PLC-&#x003b3;, and STAT1 [<xref ref-type="bibr" rid="td.REF.cohen.2002.304">Cohen 2002</xref>, <xref ref-type="bibr" rid="td.REF.torley.2002.1096">Torley et al 2002</xref>]. After activation, the complex is internalized for signal downregulation. This is accomplished via one of two pathways [<xref ref-type="bibr" rid="td.REF.lievens.2006.783">Lievens et al 2006</xref>]: ubiquitination and degradation of the activated FGFR or feedback from the end targets (namely ERK) through the docking protein FRS2&#x003b1;.</p>
        <p>FGFR3 consists of an extracellular signal peptide, three immunoglobulin-like domains (IgI, IgII, and IgIII) with an acid box between IgI and IgII, a transmembrane domain, and a split intracellular tyrosine kinase domain [<xref ref-type="bibr" rid="td.REF.hyland.2003.157">Hyland et al 2003</xref>]. Ligand binding occurs between IgII and IgIII [<xref ref-type="bibr" rid="td.REF.mcintosh.2000.85">McIntosh et al 2000</xref>]. The normal function of <italic toggle="yes">FGFR3</italic> is to serve as a negative regulator of bone growth during ossification [<xref ref-type="bibr" rid="td.REF.legeaimallet.1998.13007">Legeai-Mallet et al 1998</xref>, <xref ref-type="bibr" rid="td.REF.cohen.2002.304">Cohen 2002</xref>]. Mice with knockout mutations of <italic toggle="yes">Fgfr3</italic> are overgrown with elongated vertebrae and long femurs and tails. The growth plates of the long bones are expanded [<xref ref-type="bibr" rid="td.REF.mcintosh.2000.85">McIntosh et al 2000</xref>, <xref ref-type="bibr" rid="td.REF.cohen.2002.304">Cohen 2002</xref>]. Alternative splicing of exons 8 and 9 has been documented, with such diversity conferring the capacity for differential expression and binding of multiple ligands [<xref ref-type="bibr" rid="td.REF.cohen.2002.304">Cohen 2002</xref>]. Three reported isoforms of FGFR3 include: the native protein, an intermediate intracellular membrane-associated glycoprotein, and a mature glycoprotein [<xref ref-type="bibr" rid="td.REF.lievens.2003.17344">Lievens &#x00026; Liboi 2003</xref>]. </p>
        <p>FGFR3 is expressed in a spatial- and temporal-specific pattern during embryogenesis [<xref ref-type="bibr" rid="td.REF.mcintosh.2000.85">McIntosh et al 2000</xref>]. The highest levels of expression occur in cartilage and the central nervous system [<xref ref-type="bibr" rid="td.REF.cohen.2002.304">Cohen 2002</xref>]. FGFR3 is also expressed in the dermis and epidermis [<xref ref-type="bibr" rid="td.REF.mcintosh.2000.85">McIntosh et al 2000</xref>, <xref ref-type="bibr" rid="td.REF.torley.2002.1096">Torley et al 2002</xref>].</p>
        <p>The FGFR3 signaling pathway is activated in several cancers, including bladder and cervical cancer and multiple myeloma. <xref ref-type="bibr" rid="td.REF.meyer.2004.28450">Meyer et al [2004]</xref> identified FGFR3 in complex with Pyk2, a focal adhesion kinase known to regulate apoptosis in multiple myeloma cells and to activate Stat5B. FGFR3 phosphorylates Pyk2 and activates a signaling pathway without recruitment of proteins from the Src family (which are normally recruited by Pyk2 in the absence of FGFR3). Hyperactivated FGFR3 (i.e., mutations similar to those causing TD) causes hyperphosphorylation of Pyk2. FGFR3 may also sequester Pyk2 from Shp2, which normally functions to decrease Pyk2 phosphorylation and downregulate Pyk2 signaling. Both FGFR3 and Pyk2 may work in concert to maximally activate Stat5B [<xref ref-type="bibr" rid="td.REF.meyer.2004.28450">Meyer et al 2004</xref>].</p>
        <p><bold>Abnormal gene product.</bold> Mutations in <italic toggle="yes">FGFR3</italic> are gain-of-function mutations that produce a constitutively active protein capable of initiating intracellular signal pathways in the absence of ligand binding [<xref ref-type="bibr" rid="td.REF.baitner.2000.594">Baitner et al 2000</xref>, <xref ref-type="bibr" rid="td.REF.cohen.2002.304">Cohen 2002</xref>]. This activation leads to premature differentiation of proliferative chondrocytes into pre-hypertrophic chondrocytes and, ultimately, to premature maturation of the bone [<xref ref-type="bibr" rid="td.REF.cohen.2002.304">Cohen 2002</xref>, <xref ref-type="bibr" rid="td.REF.legeaimallet.2004.26">Legeai-Mallet et al 2004</xref>]. The mechanism for other clinical findings in TD type I and TD type II (CNS and dermal abnormalities) is less clear. All reported mutations cause constitutive activation through the creation of new, unpaired cysteine residues that induce ligand-independent dimerization [<xref ref-type="bibr" rid="td.REF.cohen.2002.304">Cohen 2002</xref>], activation of the tyrosine kinase loop [<xref ref-type="bibr" rid="td.REF.tavormina.1999.722">Tavormina et al 1999</xref>, <xref ref-type="bibr" rid="td.REF.cohen.2002.304">Cohen 2002</xref>], or creation of an elongated protein through destruction of the native stop codon.</p>
        <p>Studies have shown that the level of ligand-independent tyrosine kinase activity conferred by different <italic toggle="yes">FGFR3</italic> mutations is correlated with the severity of disorganization of endochondral ossification and, therefore, with the skeletal phenotype [<xref ref-type="bibr" rid="td.REF.bellus.1999.53">Bellus et al 1999</xref>, <xref ref-type="bibr" rid="td.REF.bellus.2000.1411">Bellus et al 2000</xref>]. </p>
        <p>The p.Lys650Glu mutation causing thanatophoric dysplasia type II has been shown to cause accumulation of intermediate, activated forms of FGFR3 in the endoplasmic reticulum [<xref ref-type="bibr" rid="td.REF.lievens.2003.17344">Lievens &#x00026; Liboi 2003</xref>]. This immature, cellular FGFR3 is able to signal through an FRS2&#x003b1;-independent pathway (via the JAK/STAT pathway) that is then not subject to FRS2&#x003b1;-mediated downregulation [<xref ref-type="bibr" rid="td.REF.lievens.2006.783">Lievens et al 2006</xref>].</p>
      </sec>
      <sec id="td.References">
        <title>References</title>
        <sec id="td.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="td.Literature_Cited.reflist0">
            <ref id="td.REF.arikawahirasawa.2001.254">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Arikawa-Hirasawa</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilcox</surname>
                    <given-names>WR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamada</surname>
                    <given-names>Y</given-names>
                  </name>
                </person-group>
                <article-title>Dyssegmental dysplasia, Silverman-Handmaker type: unexpected role of perlecan in cartilage development.</article-title>
                <source>Am J Med Genet</source>
                <year>2001</year>
                <volume>106</volume>
                <fpage>254</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">11891676</pub-id>
              </element-citation>
            </ref>
            <ref id="td.REF.baitner.2000.594">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Baitner</surname>
                    <given-names>AC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maurer</surname>
                    <given-names>SG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gruen</surname>
                    <given-names>MB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Di Cesare</surname>
                    <given-names>PE</given-names>
                  </name>
                </person-group>
                <article-title>The genetic basis of the osteochondrodysplasias.</article-title>
                <source>J Pediatr Orthop</source>
                <year>2000</year>
                <volume>20</volume>
                <fpage>594</fpage>
                <lpage>605</lpage>
                <pub-id pub-id-type="pmid">11008738</pub-id>
              </element-citation>
            </ref>
            <ref id="td.REF.barbosabuck.2012.1038">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Barbosa-Buck</surname>
                    <given-names>CO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Orioli</surname>
                    <given-names>IM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dutra</surname>
                    <given-names>MG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lopez-Camelo</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Castilla</surname>
                    <given-names>EE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cavalcanti</surname>
                    <given-names>DP</given-names>
                  </name>
                </person-group>
                <article-title>Clinical epidemiology of skeletal dysplasias in South America.</article-title>
                <source>Am J Med Genet Part A</source>
                <year>2012</year>
                <volume>158A</volume>
                <fpage>1038</fpage>
                <lpage>45</lpage>
                <pub-id pub-id-type="pmid">22407836</pub-id>
              </element-citation>
            </ref>
            <ref id="td.REF.bellus.1999.53">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bellus</surname>
                    <given-names>GA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bamshad</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Przylepa</surname>
                    <given-names>KA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dorst</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>RR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hurko</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jabs</surname>
                    <given-names>EW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Curry</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilcox</surname>
                    <given-names>WR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lachman</surname>
                    <given-names>RS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rimoin</surname>
                    <given-names>DL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Francomano</surname>
                    <given-names>CA</given-names>
                  </name>
                </person-group>
                <article-title>Severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN): phenotypic analysis of a new skeletal dysplasia caused by a Lys650Met mutation in fibroblast growth factor receptor 3.</article-title>
                <source>Am J Med Genet</source>
                <year>1999</year>
                <volume>85</volume>
                <fpage>53</fpage>
                <lpage>65</lpage>
                <pub-id pub-id-type="pmid">10377013</pub-id>
              </element-citation>
            </ref>
            <ref id="td.REF.bellus.2000.1411">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bellus</surname>
                    <given-names>GA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spector</surname>
                    <given-names>EB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Speiser</surname>
                    <given-names>PW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weaver</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garber</surname>
                    <given-names>AT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bryke</surname>
                    <given-names>CR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Israel</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rosengren</surname>
                    <given-names>SS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Webster</surname>
                    <given-names>MK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Donoghue</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Francomano</surname>
                    <given-names>CA</given-names>
                  </name>
                </person-group>
                <article-title>Distinct missense mutations of the FGFR3 lys650 codon modulate receptor kinase activation and the severity of the skeletal dysplasia phenotype.</article-title>
                <source>Am J Hum Genet</source>
                <year>2000</year>
                <volume>67</volume>
                <fpage>1411</fpage>
                <lpage>21</lpage>
                <pub-id pub-id-type="pmid">11055896</pub-id>
              </element-citation>
            </ref>
            <ref id="td.REF.brodie.1999.476">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Brodie</surname>
                    <given-names>SG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kitoh</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lachman</surname>
                    <given-names>RS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nolasco</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mekikian</surname>
                    <given-names>PB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilcox</surname>
                    <given-names>WR</given-names>
                  </name>
                </person-group>
                <article-title>Platyspondylic lethal skeletal dysplasia, San Diego type, is caused by FGFR3 mutations.</article-title>
                <source>Am J Med Genet</source>
                <year>1999</year>
                <volume>84</volume>
                <fpage>476</fpage>
                <lpage>80</lpage>
                <pub-id pub-id-type="pmid">10360402</pub-id>
              </element-citation>
            </ref>
            <ref id="td.REF.camera.2001.277">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Camera</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baldi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Strisciuglio</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Concolino</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mastroiacovo</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baffico</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>Occurrence of thanatophoric dysplasia type I (R248C) and hypochondroplasia (N540K) mutations in two patients with achondroplasia phenotype.</article-title>
                <source>Am J Med Genet</source>
                <year>2001</year>
                <volume>104</volume>
                <fpage>277</fpage>
                <lpage>81</lpage>
                <pub-id pub-id-type="pmid">11754059</pub-id>
              </element-citation>
            </ref>
            <ref id="td.REF.chen.2001.89">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>CP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chern</surname>
                    <given-names>SR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shih</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yeh</surname>
                    <given-names>LF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chang</surname>
                    <given-names>TY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tzen</surname>
                    <given-names>CY</given-names>
                  </name>
                </person-group>
                <article-title>Prenatal diagnosis and genetic analysis of type I and type II thanatophoric dysplasia.</article-title>
                <source>Prenat Diagn</source>
                <year>2001</year>
                <volume>21</volume>
                <fpage>89</fpage>
                <lpage>95</lpage>
                <pub-id pub-id-type="pmid">11241532</pub-id>
              </element-citation>
            </ref>
            <ref id="td.REF.cohen.2002.304">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cohen</surname>
                    <given-names>MM</given-names>
                    <suffix>Jr</suffix>
                  </name>
                </person-group>
                <article-title>Some chondrodysplasias with short limbs: molecular perspectives.</article-title>
                <source>Am J Med Genet</source>
                <year>2002</year>
                <volume>112</volume>
                <fpage>304</fpage>
                <lpage>13</lpage>
                <pub-id pub-id-type="pmid">12357475</pub-id>
              </element-citation>
            </ref>
            <ref id="td.REF.debiasio.2005.426">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>De Biasio</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ichim</surname>
                    <given-names>IB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scarso</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baldi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barban</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Venturini</surname>
                    <given-names>PL</given-names>
                  </name>
                </person-group>
                <article-title>Thanatophoric dysplasia type I presenting with increased nuchal translucency in the first trimester.</article-title>
                <source>Prenat Diagn</source>
                <year>2005</year>
                <volume>25</volume>
                <fpage>426</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">15906417</pub-id>
              </element-citation>
            </ref>
            <ref id="td.REF.debiasio.2000.835">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>De Biasio</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prefumo</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baffico</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baldi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Priolo</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lerone</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Toma</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Venturini</surname>
                    <given-names>PL</given-names>
                  </name>
                </person-group>
                <article-title>Sonographic and molecular diagnosis of thanatophoric dysplasia type I at 18 weeks of gestation.</article-title>
                <source>Prenat Diagn</source>
                <year>2000</year>
                <volume>20</volume>
                <fpage>835</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">11038465</pub-id>
              </element-citation>
            </ref>
            <ref id="td.REF.donnelly.2010.114">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Donnelly</surname>
                    <given-names>DE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McConnell</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Paterson</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morrison</surname>
                    <given-names>PJ</given-names>
                  </name>
                </person-group>
                <article-title>The prevalence of thanatophoric dysplasia and lethal osteogenesis imperfecta type II in Northern Ireland - a complete population study.</article-title>
                <source>Ulster Med J.</source>
                <year>2010</year>
                <volume>79</volume>
                <fpage>114</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">22375084</pub-id>
              </element-citation>
            </ref>
            <ref id="td.REF.ferreira.2004.241">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ferreira</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matias</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brandao</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Montenegro</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <article-title>Nuchal translucency and ductus venosus blood flow as early sonographic markers of thanatophoric dysplasia. A case report.</article-title>
                <source>Fetal Diagn Ther</source>
                <year>2004</year>
                <volume>19</volume>
                <fpage>241</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">15067234</pub-id>
              </element-citation>
            </ref>
            <ref id="td.REF.hyland.2003.157">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hyland</surname>
                    <given-names>VJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robertson</surname>
                    <given-names>SP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Flanagan</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Savarirayan</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roscioli</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Masel</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hayes</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Glass</surname>
                    <given-names>IA</given-names>
                  </name>
                </person-group>
                <article-title>Somatic and germline mosaicism for a R248C missense mutation in FGFR3, resulting in a skeletal dysplasia distinct from thanatophoric dysplasia.</article-title>
                <source>Am J Med Genet A</source>
                <year>2003</year>
                <volume>120A</volume>
                <fpage>157</fpage>
                <lpage>68</lpage>
                <pub-id pub-id-type="pmid">12833394</pub-id>
              </element-citation>
            </ref>
            <ref id="td.REF.khalil.2011.115">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Khalil</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pajkrt</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chitty</surname>
                    <given-names>LS</given-names>
                  </name>
                </person-group>
                <article-title>Early prenatal diagnosis of skeletal anomalies.</article-title>
                <source>Prenat Diagn.</source>
                <year>2011</year>
                <volume>31</volume>
                <fpage>115</fpage>
                <lpage>24</lpage>
                <pub-id pub-id-type="pmid">21210484</pub-id>
              </element-citation>
            </ref>
            <ref id="td.REF.krakow.2008.1917">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Krakow</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alanay</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rimoin</surname>
                    <given-names>LP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lin</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilcox</surname>
                    <given-names>WR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lachman</surname>
                    <given-names>RS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rimoin</surname>
                    <given-names>DL</given-names>
                  </name>
                </person-group>
                <article-title>Evaluation of prenatal-onset osteochondrodysplasias by ultrasonography: a retrospective and prospective analysis.</article-title>
                <source>Am J Med Genet A.</source>
                <year>2008</year>
                <volume>146A</volume>
                <fpage>1917</fpage>
                <lpage>24</lpage>
                <pub-id pub-id-type="pmid">18627037</pub-id>
              </element-citation>
            </ref>
            <ref id="td.REF.lee.2002.113">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>SH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cho</surname>
                    <given-names>JY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Song</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Min</surname>
                    <given-names>JY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Han</surname>
                    <given-names>BH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>YH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cho</surname>
                    <given-names>BJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kim</surname>
                    <given-names>SH</given-names>
                  </name>
                </person-group>
                <article-title>Fetal musculoskeletal malformations with a poor outcome: ultrasonographic, pathologic, and radiographic findings.</article-title>
                <source>Korean J Radiol</source>
                <year>2002</year>
                <volume>3</volume>
                <fpage>113</fpage>
                <lpage>24</lpage>
                <pub-id pub-id-type="pmid">12087201</pub-id>
              </element-citation>
            </ref>
            <ref id="td.REF.legeaimallet.1998.13007">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Legeai-Mallet</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Benoist-Lasselin</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Delezoide</surname>
                    <given-names>AL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Munnich</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bonaventure</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <article-title>Fibroblast growth factor receptor 3 mutations promote apoptosis but do not alter chondrocyte proliferation in thanatophoric dysplasia.</article-title>
                <source>J Biol Chem</source>
                <year>1998</year>
                <volume>273</volume>
                <fpage>13007</fpage>
                <lpage>14</lpage>
                <pub-id pub-id-type="pmid">9582336</pub-id>
              </element-citation>
            </ref>
            <ref id="td.REF.legeaimallet.2004.26">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Legeai-Mallet</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Benoist-Lasselin</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Munnich</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bonaventure</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <article-title>Overexpression of FGFR3, Stat1, Stat5 and p21Cip1 correlates with phenotypic severity and defective chondrocyte differentiation in FGFR3-related chondrodysplasias.</article-title>
                <source>Bone</source>
                <year>2004</year>
                <volume>34</volume>
                <fpage>26</fpage>
                <lpage>36</lpage>
                <pub-id pub-id-type="pmid">14751560</pub-id>
              </element-citation>
            </ref>
            <ref id="td.REF.lemyre.1999.185">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lemyre</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Azouz</surname>
                    <given-names>EM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Teebi</surname>
                    <given-names>AS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Glanc</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>MF</given-names>
                  </name>
                </person-group>
                <article-title>Bone dysplasia series. Achondroplasia, hypochondroplasia and thanatophoric dysplasia: review and update.</article-title>
                <source>Can Assoc Radiol J</source>
                <year>1999</year>
                <volume>50</volume>
                <fpage>185</fpage>
                <lpage>97</lpage>
                <pub-id pub-id-type="pmid">10405653</pub-id>
              </element-citation>
            </ref>
            <ref id="td.REF.lievens.2003.17344">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lievens</surname>
                    <given-names>PM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Liboi</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <article-title>The thanatophoric dysplasia type II mutation hampers complete maturation of fibroblast growth factor receptor 3 (FGFR3), which activates signal transducer and activator of transcription 1 (STAT1) from the endoplasmic reticulum.</article-title>
                <source>J Biol Chem</source>
                <year>2003</year>
                <volume>278</volume>
                <fpage>17344</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">12624096</pub-id>
              </element-citation>
            </ref>
            <ref id="td.REF.lievens.2006.783">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lievens</surname>
                    <given-names>PM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roncador</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Liboi</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <article-title>K644E/M FGFR3 mutants activate Erk1/2 from the endoplasmic reticulum through FRS2 alpha and PLC gamma-independent pathways.</article-title>
                <source>J Mol Biol</source>
                <year>2006</year>
                <volume>357</volume>
                <fpage>783</fpage>
                <lpage>92</lpage>
                <pub-id pub-id-type="pmid">16476447</pub-id>
              </element-citation>
            </ref>
            <ref id="td.REF.macdonald.1989.508">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>MacDonald</surname>
                    <given-names>IM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hunter</surname>
                    <given-names>AG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>MacLeod</surname>
                    <given-names>PM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>MacMurray</surname>
                    <given-names>SB</given-names>
                  </name>
                </person-group>
                <article-title>Growth and development in thanatophoric dysplasia.</article-title>
                <source>Am J Med Genet</source>
                <year>1989</year>
                <volume>33</volume>
                <fpage>508</fpage>
                <lpage>12</lpage>
                <pub-id pub-id-type="pmid">2596513</pub-id>
              </element-citation>
            </ref>
            <ref id="td.REF.mansour.1995.415">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mansour</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hall</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pembrey</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Young</surname>
                    <given-names>ID</given-names>
                  </name>
                </person-group>
                <article-title>A clinical and genetic study of campomelic dysplasia.</article-title>
                <source>J Med Genet</source>
                <year>1995</year>
                <volume>32</volume>
                <fpage>415</fpage>
                <lpage>20</lpage>
                <pub-id pub-id-type="pmid">7666392</pub-id>
              </element-citation>
            </ref>
            <ref id="td.REF.marquisnicholson.2013.80">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Marquis-Nicholson</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aftimos</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Love</surname>
                    <given-names>DR</given-names>
                  </name>
                </person-group>
                <article-title>Molecular Analysis of a Case of Thanatophoric Dysplasia Reveals Two de novo FGFR3 Missense Mutations located in cis.</article-title>
                <source>Sultan Qaboos Univ Med J.</source>
                <year>2013</year>
                <volume>13</volume>
                <fpage>80</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">23573386</pub-id>
              </element-citation>
            </ref>
            <ref id="td.REF.martinezfrias.2011.197">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mart&#x000ed;nez-Fr&#x000ed;as</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eg&#x000fc;&#x000e9;s</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Puras</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hualde</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Frutos</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bermejo</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nieto</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mart&#x000ed;nez</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <article-title>Thanatophoric dysplasia type II with encephalocele and semilobar holoprosencephaly: Insights into its pathogenesis.</article-title>
                <source>Am J Med Genet A.</source>
                <year>2011</year>
                <volume>155A</volume>
                <fpage>197</fpage>
                <lpage>202</lpage>
                <pub-id pub-id-type="pmid">21204232</pub-id>
              </element-citation>
            </ref>
            <ref id="td.REF.mcintosh.2000.85">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>McIntosh</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bellus</surname>
                    <given-names>GA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jab</surname>
                    <given-names>EW</given-names>
                  </name>
                </person-group>
                <article-title>The pleiotropic effects of fibroblast growth factor receptors in mammalian development.</article-title>
                <source>Cell Struct Funct</source>
                <year>2000</year>
                <volume>25</volume>
                <fpage>85</fpage>
                <lpage>96</lpage>
                <pub-id pub-id-type="pmid">10885578</pub-id>
              </element-citation>
            </ref>
            <ref id="td.REF.meyer.2004.28450">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Meyer</surname>
                    <given-names>AN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gastwirt</surname>
                    <given-names>RF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schlaepfer</surname>
                    <given-names>DD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Donoghue</surname>
                    <given-names>DJ</given-names>
                  </name>
                </person-group>
                <article-title>The cytoplasmic tyrosine kinase Pyk2 as a novel effector of fibroblast growth factor receptor 3 activation.</article-title>
                <source>J Biol Chem</source>
                <year>2004</year>
                <volume>279</volume>
                <fpage>28450</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">15105428</pub-id>
              </element-citation>
            </ref>
            <ref id="td.REF.neumann.2003.786">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Neumann</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kunze</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Uhl</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stover</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zabel</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spranger</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <article-title>Survival to adulthood and dominant inheritance of platyspondylic skeletal dysplasia, Torrance-Luton type.</article-title>
                <source>Pediatr Radiol</source>
                <year>2003</year>
                <volume>33</volume>
                <fpage>786</fpage>
                <lpage>90</lpage>
                <pub-id pub-id-type="pmid">12961049</pub-id>
              </element-citation>
            </ref>
            <ref id="td.REF.nishimura.2004.75">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nishimura</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nakashima</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mabuchi</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shimamoto</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shimamoto</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shimao</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nagai</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamaguchi</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kosaki</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ohashi</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Makita</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ikegawa</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <article-title>Identification of COL2A1 mutations in platyspondylic skeletal dysplasia, Torrance type.</article-title>
                <source>J Med Genet</source>
                <year>2004</year>
                <volume>41</volume>
                <fpage>75</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">14729840</pub-id>
              </element-citation>
            </ref>
            <ref id="td.REF.pannier.2009.1296">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pannier</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martinovic</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heuertz</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Delezoide</surname>
                    <given-names>AL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Munnich</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schibler</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Serre</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Legeai-Mallet</surname>
                    <given-names>L</given-names>
                  </name>
                </person-group>
                <article-title>Thanatophoric dysplasia caused by double missense FGFR3 mutations.</article-title>
                <source>Am J Med Genet A.</source>
                <year>2009</year>
                <volume>149A</volume>
                <fpage>1296</fpage>
                <lpage>301</lpage>
                <pub-id pub-id-type="pmid">19449430</pub-id>
              </element-citation>
            </ref>
            <ref id="td.REF.parilla.2003.255">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Parilla</surname>
                    <given-names>BV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leeth</surname>
                    <given-names>EA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kambich</surname>
                    <given-names>MP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chillis</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>MacGregor</surname>
                    <given-names>SN</given-names>
                  </name>
                </person-group>
                <article-title>Antenatal detection of skeletal dysplasias.</article-title>
                <source>J Ultrasound Med</source>
                <year>2003</year>
                <volume>22</volume>
                <fpage>255</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">12636325</pub-id>
              </element-citation>
            </ref>
            <ref id="td.REF.passosbueno.1999.115">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Passos-Bueno</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilcox</surname>
                    <given-names>WR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jabs</surname>
                    <given-names>EW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sertie</surname>
                    <given-names>AL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alonso</surname>
                    <given-names>LG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kitoh</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <article-title>Clinical spectrum of fibroblast growth factor receptor mutations.</article-title>
                <source>Hum Mutat</source>
                <year>1999</year>
                <volume>14</volume>
                <fpage>115</fpage>
                <lpage>25</lpage>
                <pub-id pub-id-type="pmid">10425034</pub-id>
              </element-citation>
            </ref>
            <ref id="td.REF.rohmann.2006.414">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rohmann</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brunner</surname>
                    <given-names>HG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kayserili</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Uyguner</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nurnberg</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lew</surname>
                    <given-names>ED</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dobbie</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eswarakumar</surname>
                    <given-names>VP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Uzumcu</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ulubil-Emeroglu</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leroy</surname>
                    <given-names>JG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Becker</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lehnerdt</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cremers</surname>
                    <given-names>CW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yuksel-Apak</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nurnberg</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kubisch</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schlessinger</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Bokhoven</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wollnik</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <article-title>Mutations in different components of FGF signaling in LADD syndrome.</article-title>
                <source>Nat Genet</source>
                <year>2006</year>
                <volume>38</volume>
                <fpage>414</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">16501574</pub-id>
              </element-citation>
            </ref>
            <ref id="td.REF.schramm.2009.160">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Schramm</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gloning</surname>
                    <given-names>KP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Minderer</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Daumer-Haas</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>H&#x000f6;rtnagel</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nerlich</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tutschek</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <article-title>Prenatal sonographic diagnosis of skeletal dysplasias.</article-title>
                <source>Ultrasound Obstet Gynecol.</source>
                <year>2009</year>
                <volume>34</volume>
                <fpage>160</fpage>
                <lpage>70</lpage>
                <pub-id pub-id-type="pmid">19548204</pub-id>
              </element-citation>
            </ref>
            <ref id="td.REF.takagi.2012.247">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Takagi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kaneko-Schmitt</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suzumori</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nishimura</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hasegawa</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <article-title>Atypical achondroplasia due to somatic mosaicism for the common thanatophoric dysplasia mutation R248C.</article-title>
                <source>Am J Med Genet Part A</source>
                <year>2012</year>
                <volume>158A</volume>
                <fpage>247</fpage>
                <lpage>50</lpage>
                <pub-id pub-id-type="pmid">22106050</pub-id>
              </element-citation>
            </ref>
            <ref id="td.REF.tavormina.1999.722">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tavormina</surname>
                    <given-names>PL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bellus</surname>
                    <given-names>GA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Webster</surname>
                    <given-names>MK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bamshad</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fraley</surname>
                    <given-names>AE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McIntosh</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Szabo</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jiang</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jabs</surname>
                    <given-names>EW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilcox</surname>
                    <given-names>WR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wasmuth</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Donoghue</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thompson</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Francomano</surname>
                    <given-names>CA</given-names>
                  </name>
                </person-group>
                <article-title>A novel skeletal dysplasia with developmental delay and acanthosis nigricans is caused by a Lys650Met mutation in the fibroblast growth factor receptor 3 gene.</article-title>
                <source>Am J Hum Genet</source>
                <year>1999</year>
                <volume>64</volume>
                <fpage>722</fpage>
                <lpage>31</lpage>
                <pub-id pub-id-type="pmid">10053006</pub-id>
              </element-citation>
            </ref>
            <ref id="td.REF.thompson.2011.92">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Thompson</surname>
                    <given-names>DR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Browd</surname>
                    <given-names>SR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sangar&#x000e9;</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rowell</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Slimp</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haberkern</surname>
                    <given-names>CM</given-names>
                  </name>
                </person-group>
                <article-title>Anesthetic management of an infant with thanatophoric dysplasia for suboccipital decompression.</article-title>
                <source>Paediatr Anaesth.</source>
                <year>2011</year>
                <volume>21</volume>
                <fpage>92</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">21155935</pub-id>
              </element-citation>
            </ref>
            <ref id="td.REF.tonni.2010.314">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tonni</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Azzoni</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ventura</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferrari</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Felice</surname>
                    <given-names>CD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baldi</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>Thanatophoric dysplasia type I associated with increased nuchal translucency in the first trimester: Early prenatal diagnosis using combined ultrasonography and molecular biology.</article-title>
                <source>Fetal Pediatr Pathol.</source>
                <year>2010</year>
                <volume>29</volume>
                <fpage>314</fpage>
                <lpage>22</lpage>
                <pub-id pub-id-type="pmid">20704477</pub-id>
              </element-citation>
            </ref>
            <ref id="td.REF.torley.2002.1096">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Torley</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bellus</surname>
                    <given-names>GA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Munro</surname>
                    <given-names>CS</given-names>
                  </name>
                </person-group>
                <article-title>Genes, growth factors and acanthosis nigricans.</article-title>
                <source>Br J Dermatol</source>
                <year>2002</year>
                <volume>147</volume>
                <fpage>1096</fpage>
                <lpage>101</lpage>
                <pub-id pub-id-type="pmid">12452857</pub-id>
              </element-citation>
            </ref>
            <ref id="td.REF.wilcox.1998.274">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wilcox</surname>
                    <given-names>WR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tavormina</surname>
                    <given-names>PL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Krakow</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kitoh</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lachman</surname>
                    <given-names>RS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wasmuth</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thompson</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rimoin</surname>
                    <given-names>DL</given-names>
                  </name>
                </person-group>
                <article-title>Molecular, radiologic, and histopathologic correlations in thanatophoric dysplasia.</article-title>
                <source>Am J Med Genet</source>
                <year>1998</year>
                <volume>78</volume>
                <fpage>274</fpage>
                <lpage>81</lpage>
                <pub-id pub-id-type="pmid">9677066</pub-id>
              </element-citation>
            </ref>
            <ref id="td.REF.zankl.2005.61">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zankl</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Neumann</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ignatius</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nikkels</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schrander-Stumpel</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mortier</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Omran</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wright</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hilbert</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bonaf&#x000e9;</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spranger</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zabel</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Superti-Furga</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <article-title>Dominant negative mutations in the C-propeptide of COL2A1 cause platyspondylic lethal skeletal dysplasia, torrance type, and define a novel subfamily within type 2 collagenopathies.</article-title>
                <source>Am J Med Genet A</source>
                <year>2005</year>
                <volume>133A</volume>
                <fpage>61</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">15643621</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="td.Suggested_Reading">
          <title>Suggested Reading</title>
          <ref-list id="td.Suggested_Reading.reflist0">
            <ref id="td.REF.bonaventure.2007.3078">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bonaventure</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Horne</surname>
                    <given-names>WC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baron</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <article-title>The localization of FGFR3 mutations causing thanatophoric dysplasia type I differently affects phosphorylation, processing and ubiquitylation of the receptor.</article-title>
                <source>FEBS J</source>
                <year>2007</year>
                <volume>274</volume>
                <fpage>3078</fpage>
                <lpage>93</lpage>
                <pub-id pub-id-type="pmid">17509076</pub-id>
              </element-citation>
            </ref>
            <ref id="td.REF.you.2007.11039">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>You</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spangler</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Han</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ghosh</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hristova</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <article-title>Effect of pathogenic cysteine mutations on FGFR3 transmembrane domain dimerization in detergents and lipid bylayers.</article-title>
                <source>Biochemistry</source>
                <year>2007</year>
                <volume>46</volume>
                <fpage>11039</fpage>
                <lpage>46</lpage>
                <pub-id pub-id-type="pmid">17845056</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="td.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="td.Acknowledgments">
          <title>Acknowledgments</title>
          <p>The authors wish to thank Julie Hoover-Fong MD, Clinical Director of the Greenberg Center for Skeletal Dysplasias at Johns Hopkins University, for her clinical insight.</p>
        </sec>
        <sec id="td.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>12 September 2013 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>30 September 2008 (cg) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>7 July 2006 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>21 May 2004 (me) Review posted to live Web site</p>
            </list-item>
            <list-item>
              <p>27 February 2004 (bk, gc) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
